POMALYST Is A New Option For Patients Whose Disease Has Progressed Despite Treatment With Available Therapies

Mississauga, Ontario (Press Release) - Health Canada has approved POMALYST™ oral ther­apy (poma­lido­mide capsules) in com­bi­na­tion with dexa­meth­a­sone, for patients with multiple myeloma for whom both lena­lido­mide and bor­tez­o­mib have failed, who have received at least two prior treat­ment regi­mens and have dem­onstrated dis­ease pro­gres­sion on their last regi­men. Until POMALYST, there have been few options for patients whose dis­ease has progressed despite being treated with traditional ther­a­pies. Treatment with POMALYST has been shown to im­prove rates of over­all survival and extend pro­gres­sion-free survival in patients who no longer respond to lena­lido­mide …

Company Now Positioned to Prepare and Initiate Pivotal Phase 3 Clinical Trial

New York, NY (Press Release) Actinium Pharma­ceu­ticals, Inc. (OTCQB:ATNM.OB) ("Actinium" or "the Company"), a bio­pharma­ceu­tical com­pany devel­op­ing inno­va­tive targeted pay­load immuno­therapeutics for the treat­ment of ad­vanced cancers, has suc­cess­fully transferred the tech­nology for the manu­fac­ture of Iomab™-B (BC8-I-131), a drug being developed for thera­peutic treat­ment of incurable blood cancers. The Company now intends to com­plete plans to scale-up, submit an Investigational New Drug (IND) Application to the U.S. Food and Drug Admin­istra­tion and ini­ti­ate a pivotal Phase 3 clin­i­cal trial …

Comprehensive Genomic Profiling May Lead To New Therapeutic Options For Patients; Data Presented at American Society of Hematology Annual Meeting

Cambridge, MA (Press Release) - Foundation Medicine today announced new data from a pilot study demonstrating that its fully informative genomic profile for hema­to­logic malig­nan­cies, FoundationOne™ Heme, identified both novel and pre­vi­ously reported clin­i­cally actionable¹ genomic alterations in multiple myeloma cases. These data were presented in an oral presentation titled Pilot Study To Evaluate The Prevalence Of Actionable Oncogenic Mutations In Patients With Relapsed Refractory Multiple Myeloma (abstract number 755) by Alexander …

− Oral Data Presentation to be Featured in “Highlights of ASH” −

New Orleans, LA & Osaka, Japan (Press Release) - Takeda Pharma­ceu­tical Company Limited (TSE:4502) today announced final Phase 1 and pre­lim­i­nary Phase 2 results of a study combining oral inves­ti­ga­tional MLN9708 admin­istered twice a week with lena­lido­mide and dexa­meth­a­sone in patients with newly diag­nosed multiple myeloma (MM). The investigators reported a com­bined com­plete response and very good partial response (CR+VGPR) rate of 76 per­cent (46/62) and a 94 per­cent over­all response rate (ORR; 58/62 ≥ partial response). Stringent com­plete response (sCR) was reached in 75 per­cent of patients …

- Additional Preclinical Data Presented on Ricolinostat in Potential New Drug Combinations and HDAC6 Biomarkers in Multiple Myeloma -

Boston, MA (Press Release) - Acetylon Pharma­ceu­ticals, Inc., the leader in the devel­op­ment of selective histone deacetylase (HDAC) inhibitors for en­hanced thera­peutic out­comes, today announced that positive interim clin­i­cal data from the two proof-of-concept clin­i­cal trials with selective HDAC6 inhibitor, ricolinostat (ACY-1215), were presented at the 55th Annual Meeting of the American Society of Hematology (ASH) in New Orleans, LA. The two trials are the Phase 1b dose escalation portion of …

- Study of LBH589 plus bor­tez­o­mib and dexa­meth­a­sone met pri­mary end­point of extending PFS compared to bor­tez­o­mib plus dexa­meth­a­sone and placebo
- LBH589 has poten­tial to be the first in its class of anticancer agents avail­able to patients with multiple myeloma
- Data will be presented at an upcoming medical congress and discussed with regu­la­tory author­i­ties world­wide

Basel, Switzerland (Press Release) - Novartis today announced that results of a Phase III trial of the in­ves­ti­ga­tional com­­pound LBH589 (panobinostat) in com­bi­na­tion with bor­tez­o­mib and dexa­meth­a­sone, met the pri­mary end­point of sig­nif­i­cantly extending pro­gres­sion-free …

Boston (Press Release) - Despite its tragic legacy of causing birth defects 50 years ago, thalido­mide – and newer drugs derived from it – has been reborn as an effective treat­ment for multiple myeloma and other cancers. How they act to slow cancer's spread, how­ever, has long defied explanation.

In a new report, scientists at Dana-Farber Cancer Institute say they have discovered that the drugs kill multiple myeloma cells by a mech­a­nism that's dif­fer­en­t from the way that they cause birth defects.

As a result, "It may be possible to develop better …